Meaxin (Imatinib)

Imatinib binds to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing their activation. This inhibition stops downstream signaling that promotes uncontrolled proliferation, leading to reduced tumor cell growth and, in many cases, programmed cell death of the cancerous cells.

The dose of Meaxin is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant medications. Only a qualified healthcare professional should set and adjust the dosing regimen.

Safety data for imatinib in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their oncologist before using Meaxin.

To request Meaxin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first approved BCR‑ABL inhibitor and remains a standard first‑line option for CML and GIST. Newer agents such as dasatinib or nilotinib may offer activity against certain resistant mutations, but they can have different side‑effect profiles and drug‑interaction potentials. Choice of therapy depends on disease characteristics and patient tolerance.

Meaxin tablets should be stored at temperatures below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct sunlight, and store it out of reach of children to maintain potency and safety.

Meaxin is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing and any dietary considerations to ensure consistent absorption.

The most serious adverse events include severe neutropenia or leukopenia, liver toxicity, and cardiac dysfunction such as heart failure. Patients should report signs of infection, jaundice, unexplained fatigue, shortness of breath, or swelling of the ankles promptly to their healthcare provider.

Meaxin is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for individuals with pre‑existing severe liver disease, uncontrolled cardiac conditions, or those who are pregnant without a clear benefit outweighing the risk.